Loading
A phase 3 trial of Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions is a phase 3 interventional study registered as NCT04538664 by Janssen Research & Development, LLC, with 308 participants enrolled, started 2020-10-13 and due to reach its primary completion in 2023-05-03. Interventions recorded: Amivantamab, Pemetrexed and Carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
308 enrolled.
95% CI 5.59 to 7.33; Figures from the ClinicalTrials.gov results section (first posted 2024-05-29), not from a publication · 95% CI 9.79 to 13.70
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)primary | Arm B: Chemotherapy Alone | 155 | 6.7 months | 0.395 (0.296 to 0.528) | <0.0001 | link |
| Arm A: Amivantamab + Chemotherapy | 153 | 11.37 months |
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Platinum agents and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, EGFR-mutated non-small-cell lung cancer and the tag pipeline.